Form 4: Procept BioRobotics Director Antal Rohit Desai Executes Stock Sales Under 10b5-1 Plan

Director Antal Rohit Desai reports multiple sales of Procept BioRobotics Corp (PRCT) stock between November 5th and November 7th, 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Antal Rohit Desai, a director of Procept BioRobotics Corp (PRCT), filed a Form 4 detailing several transactions involving the company's common stock.
• The transactions occurred between November 5th and November 7th, 2024.
• These transactions involved both the distribution of shares from investment funds and sales of shares held by The 2:22 DNA Trust.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2024.
• Shares were sold at prices ranging from $93.75 to $98.82.
• Distributions from White Tailed Ptarmigan, LP, Mallard Fund, L.P., and Kestrel Fund, L.P. occurred on November 5, 2024, at no consideration.
• These distributions included shares exempt from Section 16 under Rule 16a-13.
• Desai disclaims beneficial ownership of shares held by the CPMG Funds and The 2:22 DNA Trust, except to the extent of any pecuniary interest.
• Following the reported transactions, The 2:22 DNA Trust continues to hold a significant number of shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. The sentiment is neutral as it simply reports facts without expressing any positive or negative views.

Risks

• The Form 4 filing indicates sales of shares by a director, which could be interpreted negatively by the market.
• However, the sales were executed under a pre-arranged 10b5-1 trading plan, which mitigates concerns about insider information.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• Shareholders may react to the news of a director selling shares, although the pre-planned nature of the sales mitigates potential concerns.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates